Current and future therapies for advanced pancreatic cancer
- 7 June 2017
- journal article
- conference paper
- Published by Wiley in Journal of Surgical Oncology
- Vol. 116 (1), 25-34
- https://doi.org/10.1002/jso.24623
Abstract
Pancreatic cancer remains a deadly disease with a 5-year survival rate of only 8%. Even after surgical resection, most patients have recurrence of their cancer. Over the last 10 years, improvements in chemotherapy regimens led to a doubling in median overall survival. Here we review the management of advanced pancreatic cancer and highlight vaccine therapy as a novel modality of treatment.Keywords
This publication has 163 references indexed in Scilit:
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trialsSurgery, 2011
- Tumor-infiltrating neutrophils in pancreatic neoplasiaLaboratory Investigation, 2011
- Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and ProgressionCancer Cell, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent MannerCancer Cell, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Inflammation and cancerNature, 2002